-
ELI LILLY AND COMPANY et al v. NANG KUANG PHARMACEUTICAL CO., LTD. et al DC
- 1:14-cv-01647
- S.D. Ind.
- Judge: Tanya Walton Pratt
+1
- Filed: 10/08/2014
- Closed: 02/21/2018
- Latest Docket Entry: 08/20/2019
- PACER
2
Plaintiffs
2
Defendants
1
Accused
Product
2
Patents-in-Suit
1,233
Days in
Litigation
-
ELI LILLY AND COMPANY et al v. NANG KUANG PHARMACEUTICAL CO., LTD. et al DC
- 1:14-cv-01647
- S.D. Ind.
- Judge: Tanya Walton Pratt
+1
- Filed: 10/08/2014
- Closed: 02/21/2018
- Latest Docket Entry: 08/20/2019
- PACER
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Referred Judge
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
9 |
The method of claim 8 wherein about 350 μg to about 1000 μg of folic acid is administered.
|
Valid
Entry 266 Entry 264 Entry 262 |
10 |
The method of claim 9 wherein 350 μg to 600 μg of folic acid is administered.
|
Valid
Entry 266 Entry 264 Entry 262 |
12 |
An improved method for administering pemetrexed disodium to a patient in need of chemotherapeutic treatment, wherein the improvement comprises: a) administration of between about 350 μg and about 1000 μg of folic acid prior to the first
view more
|
Valid
Entry 266 Entry 264 Entry 262 |
13 |
The method of claim 12 further comprising the administration of cisplatin to the patient.
|
Valid
Entry 266 Entry 262 |
14 |
The method of claim 12, wherein vitamin B12 is administered as an intramuscular injection of about 500 μg to about 1500 μg.
|
Valid
Entry 266 Entry 264 Entry 262 |
15 |
The method of claim 14, wherein vitamin B12 is administered as an intramuscular injection of about 1000 μg.
|
Valid
Entry 266 Entry 264 Entry 262 |
18 |
The method of claim 17 wherein 350 μg to 600 μg of folic acid is administered.
|
Valid
Entry 266 Entry 264 Entry 262 |
19 |
The method of claim 18 wherein folic acid is administered 1 to 3 weeks prior to the first administration of the pemetrexed disodium.
|
Valid
Entry 266 Entry 264 Entry 262 |
21 |
The method of claim 12, 18, or 19, wherein the vitamin B12 administration is repeated about every 6 to about every 12 weeks following the administration of vitamin B12 until administration of pemetrexed disodium is discontinued.
|
Valid
Entry 266 Entry 264 Entry 262 |
22 |
The method of claim 21 further comprising the administration of cisplatin to the patient.
|
Valid
Entry 266 Entry 262 |
-
Infringement
Canda NX-2 LLC
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
10 mg base/vial, 50 mg base/vial pemetrexed disodium for intravenous infusion | US 7,772,209 B2 |
9, 10, 12, 13, 14, 15, 18, 19, 21, 22
|
Infringement
Entry 262
|
Emcure Pharmaceuticals Limited
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
10 mg base/vial, 50 mg base/vial pemetrexed disodium for intravenous infusion | US 7,772,209 B2 |
9, 10, 12, 13, 14, 15, 18, 19, 21, 22
|
Infringement
Entry 266
|
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
10 mg base/vial, 50 mg base/vial pemetrexed disodium for intravenous infusion | US 7,772,209 B2 |
9, 10, 12, 13, 14, 15, 18, 19, 21, 22
|
Infringement
Entry 266
|
Heritage Pharma Labs Inc.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
10 mg base/vial, 50 mg base/vial pemetrexed disodium for intravenous infusion | US 7,772,209 B2 |
9, 10, 12, 13, 14, 15, 18, 19, 21, 22
|
Infringement
Entry 266
|
Mylan Incorporated
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
10 mg base/vial, 50 mg base/vial pemetrexed disodium for intravenous infusion | US 7,772,209 B2 |
9, 10, 12, 14, 15, 18, 19, 21
|
Infringement
Entry 264
|
Mylan Laboratories Limited
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
10 mg base/vial, 50 mg base/vial pemetrexed disodium for intravenous infusion | US 7,772,209 B2 |
9, 10, 12, 14, 15, 18, 19, 21
|
Infringement
Entry 264
|
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
10 mg base/vial, 50 mg base/vial pemetrexed disodium for intravenous infusion | US 7,772,209 B2 |
9, 10, 12, 13, 14, 15, 18, 19, 21, 22
|
Infringement
Entry 262
|